The Meso-Scale Discovery (MSD) platform is a high-sensitivity, multiplex cytokine profiling analysis system, enabling you to simultaneously quantify multiple target cytokines, chemokines, antibodies, and growth factors from minute sample volumes (as low as 1 µL). By including MSD in your preclinical studies, you can:
- Measure high-and low-abundance targets in the same sample with high sensitivity across different sample matrices (blood, CSF, cell lysates)
- Detect both pro- and anti-inflammatory cytokines linked to tumor microenvironment (TME) modulation
- Obtain reliable quantification data of cytokine release post-treatment to evaluate therapeutic efficacy and safety
- Leverage InnoSer’s expertise in MSD by selecting already validated panels or customizing new panels
One of most recent studies performed at InnoSer has focused on quantifying the systemic immune responses to different formulations of mRNA vaccines (Figure 1). In this case, multiplex cytokine profiling via MSD offers valuable insights into modulating cytokine profiles, immune cell recruitment, and immune memory formation. These findings have direct implications for mRNA-based cancer vaccines and/or immunotherapies, enabling you to closely fine-tune the immune response based for e.g., on optimization of different formulations or mRNA constructs, avoiding any immune-related adverse events.

FIGURE 1. Multiplex cytokine profiling results following immunogenicity and tolerability study comparing different mRNA-LNP vaccine formulations (A-D represent different test article formulations). Cytokine levels induced by the various mRNA-LNP formulations were assessed from blood serum taken on day 3 (group D) and day 1 (figures A-C) following vaccine administration and quantified via meso-scale discovery (MSD) assay. Data is shown as mean ± SEM.
Comprehensive Biomarker Profiling
Are you exploring innovative strategies for cancer immunotherapies? In addition to expertise with MSD, InnoSer provides a comprehensive suite of biomarker analysis platforms to support oncology research, including:
- Flow Cytometry: Phenotyping of immune cell populations and tumor-infiltrating lymphocytes. View example data by clicking here.
- (Multiplex) ELISA: High-sensitivity detection of soluble immune mediators.
- qPCR: Gene expression analysis of immune activation markers.
- Histopathology & IHC: Spatial profiling of immune infiltrates within tumor tissues, analyzed by in-house veterinary pathologists. View example tumor microenvironment profiling data by clicking here.
Partner with InnoSer for faster, more informed decision-making today. At InnoSer, our biomarker profiling capabilities are integrated into an immuno-oncology resarch platform that includes preclinical model selection, in vivo imaging and PK/PD profiling studies. Curious to learn more? Let’s discuss how our expertise can support your oncology program.
Be the first to know – get this news straight to your inbox
InnoSer provides a variety of validated in vitro and in vivo screening tests for immunology and oncology. If you require additional information, feel free to reach out, and we will respond within a few days.
We provide a monthly update from our oncology labs containing scientific insights into our research services. To get news straight to your inbox please sign up here.